5.0Sep 30, 2020Top tier venture capital fundAnonymous employeeCurrent employee, more than 3 yearsRecommendCEO approvalBusiness outlookProsWell entrenched in the biotech ecosystemConsBroad mandate, therapeutics focused, less focus on growth equity and later stageShow more
